Meropenem-Vaborbactam

DRUG6 trials

Conditions

Acute PyelonephritisAcute Pyelonephritis (AP)Bloodstream InfectionCarbapenem Resistant Bacterial InfectionComplicated Urinary Tract InfectionComplicated Urinary Tract Infection (cUTI)HealthyHospital Acquired Bacterial Pneumonia

Phase 1

Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers

CompletedNCT03564158

Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)Healthy

Start: 2018-05-01End: 2018-11-19Updated: 2019-01-10

Phase 2

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

RecruitingNCT06672978

Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)Acute Pyelonephritis, Complicated Urinary Tract Infection

Start: 2025-06-03End: 2027-07-31Target: 66Updated: 2025-12-17

A Multi-Center, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vabomere (meropenem-vaborbactam) in the Treatment of Children with Complicated Urinary Tract Infection, Including Acute Pyelonephritis

RecruitingCTIS2024-516360-29-00

Rempex Pharmaceuticals Inc.Acute Pyelonephritis (AP), Complicated Urinary Tract Infection (cUTI)

Start: 2025-04-25Target: 36Updated: 2025-07-28

Phase 3

Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP

CompletedNCT02166476

Melinta Therapeutics, Inc.Acute Pyelonephritis, Urinary Tract Infection Complicated

Start: 2014-11-20End: 2016-04-28Updated: 2018-06-11

A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

WithdrawnNCT03006679

Melinta Therapeutics, Inc.Hospital-Acquired Bacterial Pneumonia, Hospital-Acquired Pneumonia, Ventilator-Associated Bacterial Pneumonia +1

Start: 2018-08-31End: 2020-12-31Updated: 2019-01-11

Phase 4

Optimising TREATment for Severe Gram-Negative Bacterial Infections

RecruitingNCT07004049

National University of SingaporeBloodstream Infection, Carbapenem Resistant Bacterial Infection, Hospital Acquired Bacterial Pneumonia +2

Start: 2025-04-21End: 2028-12-31Target: 600Updated: 2025-06-04

Related Papers

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection

JAMA2018-02-27298 citations